Sulfanilamide

Last updated
Sulfanilamide
Sulfanilamide-skeletal.svg
Sulfanilamida-3D.png
Clinical data
AHFS/Drugs.com salonemide Consumer Drug Information
ATC code
Identifiers
  • 4-amino benzene sulfonamide...
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.513 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6H8N2O2S
Molar mass 172.20 g·mol−1
3D model (JSmol)
Density 1.08 g/cm3
Melting point 165 °C (329 °F)
  • O=S(=O)(c1ccc(N)cc1)N
  • InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10) Yes check.svgY
  • Key:FDDDEECHVMSUSB-UHFFFAOYSA-N Yes check.svgY
   (verify)

Sulfanilamide (also spelled sulphanilamide) is a sulfonamide antibacterial drug. Chemically, it is an organic compound consisting of an aniline derivatized with a sulfonamide group. [1] Powdered sulfanilamide was used by the Allies in World War II to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars. [2] [3] Sulfanilamide is rarely if ever used systemically due to toxicity and because more effective sulfonamides are available for this purpose. Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use today in the form of topical preparations, primarily for treatment of vaginal yeast infections such as vulvovaginitis caused by Candida albicans . [4] [5] [6] [7]

Contents

The term "sulfanilamides" is also sometimes used to describe a family of molecules containing these functional groups. Examples include:

Mechanism of action

As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting (that is, by acting as a substrate analogue of) enzymatic reactions involving para-aminobenzoic acid (PABA). [8] [9] Specifically, it competitively inhibits the enzyme dihydropteroate synthase. [5] [10] PABA is needed in enzymatic reactions that produce folic acid, which acts as a coenzyme in the synthesis of purines and pyrimidines. Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria. [11]

However, this effect can be reversed by adding the end products of one-carbon transfer reactions, such as thymidine, purines, methionine, and serine. PABA can also reverse the effects of sulfonamides. [5] [12] [11]

History

Sulfanilamide was first prepared in 1908 by the Austrian chemist Paul Josef Jakob Gelmo (1879–1961) [13] [14] as part of his dissertation for a doctoral degree from the Technische Hochschule of Vienna. [15] It was patented in 1909. [16]

Gerhard Domagk, who directed the testing of the prodrug Prontosil in 1935, [17] and Jacques Tréfouël and Thérèse Tréfouël, who along with Federico Nitti and Daniel Bovet in the laboratory of Ernest Fourneau at the Pasteur Institute, determined sulfanilamide as the active form, [18] are generally credited with the discovery of sulfanilamide as a chemotherapeutic agent. Domagk was awarded the Nobel Prize for his work. [19]

In 1937, Elixir sulfanilamide, a medicine consisting of sulfanilamide dissolved in diethylene glycol, poisoned and killed more than one hundred people as a result of acute kidney failure, prompting new US regulations for drug testing. In 1938, the Food, Drug and Cosmetic Act was passed. It was only the solvent and not the sulfanilamide that was the problem, as sulfanilamide was widely and safely used at the time in both tablet and powder form. [20]

Chemical and physical properties

Laboratory synthesized sulfanilamide Sulfanilamid.jpg
Laboratory synthesized sulfanilamide

Sulfanilamide is a yellowish-white or white crystal or fine powder. It has a density of 1.08 g/cm3 and a melting point of 164.5-166.5 °C. The pH of a 0.5% aqueous solution of Sulfanilamide is 5.8 to 6.1. It has a λmax of 255 and 312 nm. [5]

Solubility: One gram of sulphanilamide dissolves in approximately 37 ml alcohol or in 5 ml acetone. It is practically insoluble in chloroform, ether, or benzene. [5]

Contraindications

Sulfanilamide is contraindicated in those known to be hypersensitive to sulfonamides, in nursing mothers, during pregnancy near term, and in infants less than two months of age. [5]

Adverse effects

Since sulfanilamide is used almost exclusively in topical vaginal preparations these days, adverse effects are typically limited to hypersensitivity or local skin reactions. If absorbed, systemic side effects commonly seen with sulfanilamides may occur. [5]

Pharmacokinetics

A small amount of sulfanilamide is absorbed following topical application or when administered as a vaginal cream or suppository (through the vaginal mucosa). It is metabolized by acetylation like other sulfonamides and excreted through the urine. [5]

See also

Related Research Articles

<span class="mw-page-title-main">Antibiotic</span> Antimicrobial substance active against bacteria

An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria. A limited number of antibiotics also possess antiprotozoal activity. Antibiotics are not effective against viruses such as the ones which cause the common cold or influenza; drugs which inhibit growth of viruses are termed antiviral drugs or antivirals rather than antibiotics. They are also not effective against fungi; drugs which inhibit growth of fungi are called antifungal drugs.

4-Aminobenzoic acid (also known as para-aminobenzoic acid or PABA because the two functional groups are attached to the benzene ring across from one another in the para position) is an organic compound with the formula H2NC6H4CO2H. PABA is a white solid, although commercial samples can appear gray. It is slightly soluble in water. It consists of a benzene ring substituted with amino and carboxyl groups. The compound occurs extensively in the natural world.

<span class="mw-page-title-main">Gerhard Domagk</span> German bacteriologist (1895–1964)

Gerhard Johannes Paul Domagk was a German pathologist and bacteriologist.

<span class="mw-page-title-main">Sulfonamide (medicine)</span> Molecular moiety or the drug class that uses it

Sulfonamide is a functional group that is the basis of several groups of drugs, which are called sulphonamides, sulfa drugs or sulpha drugs. The original antibacterial sulfonamides are synthetic (nonantibiotic) antimicrobial agents that contain the sulfonamide group. Some sulfonamides are also devoid of antibacterial activity, e.g., the anticonvulsant sultiame. The sulfonylureas and thiazide diuretics are newer drug groups based upon the antibacterial sulfonamides.

<span class="mw-page-title-main">Clindamycin</span> Antibiotic

Clindamycin is a lincosamide antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media, and endocarditis. It can also be used to treat acne, and some cases of methicillin-resistant Staphylococcus aureus (MRSA). In combination with quinine, it can be used to treat malaria. It is available by mouth, by injection into a vein, and as a cream or a gel to be applied to the skin or in the vagina.

<span class="mw-page-title-main">Dapsone</span> Antibiotic medication

Dapsone, also known as 4,4'-sulfonyldianiline (SDA) or diaminodiphenyl sulfone (DDS), is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. It is a second-line medication for the treatment and prevention of pneumocystis pneumonia and for the prevention of toxoplasmosis in those who have poor immune function. Additionally, it has been used for acne, dermatitis herpetiformis, and various other skin conditions. Dapsone is available both topically and by mouth.

<span class="mw-page-title-main">Sulfamethoxazole</span> Chemical compound

Sulfamethoxazole is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Escherichia coli and Listeria monocytogenes.

An antimetabolite is a chemical that inhibits the use of a metabolite, which is another chemical that is part of normal metabolism. Such substances are often similar in structure to the metabolite that they interfere with, such as the antifolates that interfere with the use of folic acid; thus, competitive inhibition can occur, and the presence of antimetabolites can have toxic effects on cells, such as halting cell growth and cell division, so these compounds are used in chemotherapy for cancer.

<span class="mw-page-title-main">Prontosil</span> An early antimicrobial drug of nonantibiotic type

Prontosil is an antibacterial drug of the sulfonamide group. It has a relatively broad effect against gram-positive cocci but not against enterobacteria. One of the earliest antimicrobial drugs, it was widely used in the mid-20th century but is little used today because better options now exist. The discovery and development of this first sulfonamide drug opened a new era in medicine, because it greatly widened the success of antimicrobial chemotherapy in an era when many physicians doubted its still largely untapped potential. At the time, disinfectant cleaners and topical antiseptic wound care were widely used but there were very few antimicrobial drugs to use safely inside living bodies. Antibiotic drugs derived from microbes, which we rely on heavily today, did not yet exist. Prontosil was discovered in 1932 by a research team at the Bayer Laboratories of the IG Farben conglomerate in Germany led by Gerhard Domagk. Domagk received the 1939 Nobel Prize in Physiology or Medicine for that discovery.

<span class="mw-page-title-main">Sulfadiazine</span> Chemical compound

Sulfadiazine is an antibiotic. Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite. It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae. It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis. It is taken by mouth. Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.

<span class="mw-page-title-main">Sulfacetamide</span> Sulfonamide antibiotic

Sulfacetamide is a sulfonamide antibiotic.

<span class="mw-page-title-main">Dihydropteroate synthase</span> Class of enzymes

Dihydropteroate synthase (DHPS) is an enzyme classified under EC 2.5.1.15. It produces dihydropteroate in bacteria, but it is not expressed in most eukaryotes including humans. This makes it a useful target for sulfonamide antibiotics, which compete with the PABA precursor.

<span class="mw-page-title-main">Tetrahydrofolic acid</span> Chemical compound

Tetrahydrofolic acid (THFA), or tetrahydrofolate, is a folic acid derivative.

<span class="mw-page-title-main">Sulfadimethoxine</span> Chemical compound

Sulfadimethoxine is a long-lasting sulfonamide antimicrobial medication used in veterinary medicine. It is used to treat many infections, including respiratory, urinary tract, enteric, and soft tissue infections and can be given as a standalone or combined with ormetoprim to broaden the target range. Like all sulfamides, sulfadimethoxine inhibits bacterial synthesis of folic acid by acting as a competitive inhibitor against PABA. It is the most common drug prescribed to dogs who have coccidiosis.

<span class="mw-page-title-main">Sulfapyridine</span> Chemical compound

Sulfapyridine is a sulfanilamide antibacterial medication. At one time, it was commonly referred to as M&B 693. Sulfapyridine is no longer prescribed for treatment of infections in humans. However, it may be used to treat linear IgA disease and has use in veterinary medicine. It is a good antibacterial drug, but its water solubility is very pH dependent. Thus there is a risk of crystallization within the bladder or urethra, which could lead to pain or blockage. As with other sulfonamides, there is a significant risk of agranulocytosis, and this, rather than the development of resistance by bacteria, is the main reason for its decline in use.

<i>The Demon Under the Microscope</i> Book by Thomas Hager

The Demon Under the Microscope: From Battlefield Hospitals to Nazi Labs, One Doctor's Heroic Search for the World's First Miracle Drug is a 2006 nonfiction book about the discovery of Prontosil, the first commercially available antibacterial antibiotic and sulfanilamide, the second commercial antibiotic. Prontosil was the first commercially available antibacterial antibiotic (with a relatively broad effect against Gram-positive cocci. It was developed in the 1930s by a research team at the Bayer Laboratories of the IG Farben conglomerate in Germany. The discovery and development of this first sulfonamide drug opened a new era in medicine.

<span class="mw-page-title-main">Sulfonamide</span> Organosulfur compounds containing –S(=O)2–N< functional group

In organic chemistry, the sulfonamide functional group is an organosulfur group with the structure R−S(=O)2−NR2. It consists of a sulfonyl group connected to an amine group. Relatively speaking this group is unreactive. Because of the rigidity of the functional group, sulfonamides are typically crystalline; for this reason, the formation of a sulfonamide is a classic method to convert an amine into a crystalline derivative which can be identified by its melting point. Many important drugs contain the sulfonamide group.

Jacques Tréfouël was a French medical chemist. He collaborated closely with his wife, Thérèse Tréfouël, including on the discovery of sulfanilamide.

<span class="mw-page-title-main">Thérèse Tréfouël</span> French biochemist

Thérèse Tréfouël was a French chemist. Along with her husband, Jacques Tréfouël, she is best known for her research on sulfamides, a novel class of antibiotic drugs.

Paul Josef Jakob Gelmo was an Austrian chemist who worked on synthetic dyes and discovered sulfanilamide in 1908, although their antibiotic properties were discovered only in 1932.

References

  1. Actor P, Chow AW, Dutko FJ, McKinlay MA. "Chemotherapeutics". Ullmann's Encyclopedia of Industrial Chemistry . Weinheim: Wiley-VCH. doi:10.1002/14356007.a06_173. ISBN   978-3527306732.
  2. Steinert D (2000). "The Use of Sulfanilamide in World War II". The History of WWII Medicine. Archived from the original on 2016-06-07.
  3. "Class 9 Items: Drugs, Chemicals and Biological Stains Sulfa Drugs". Library of Congress Web Archives. Archived from the original on 2013-12-04. Retrieved 2014-06-13.
  4. "Sulfanilamide". PubChem. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine.
  5. 1 2 3 4 5 6 7 8 Scholar E (2007-01-01). "Sulfanilamide". In Enna SJ, Bylund DB (eds.). xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier. pp. 1–5. doi:10.1016/b978-008055232-3.62694-7. ISBN   978-0-08-055232-3 . Retrieved 2021-10-02.
  6. "US FDA Label: AVC (sulfanilamide) Vaginal Cream 15%" (PDF). United States Food & Drug Administration. Retrieved 3 October 2021.
  7. "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Retrieved 2021-10-02.
  8. Castelli LA, Nguyen NP, Macreadie IG (May 2001). "Sulfa drug screening in yeast: fifteen sulfa drugs compete with p-aminobenzoate in Saccharomyces cerevisiae". FEMS Microbiology Letters. 199 (2): 181–4. doi: 10.1111/j.1574-6968.2001.tb10671.x . PMID   11377864.
  9. Kent M (2000). Advanced Biology. Oxford University Press. p. 46. ISBN   978-0-19-914195-1.
  10. Sharma S (January 1997). "Chapter 18 - Antifolates". In Sharma S, Anand N (eds.). Pharmacochemistry Library. Approaches to Design and Synthesis of Antiparasitic Drugs. Vol. 25. Elsevier. pp. 439–454. doi:10.1016/s0165-7208(97)80040-2. ISBN   9780444894762.
  11. 1 2 Brunton LL, Hilal-Dandan R, Knollmann BC (2018). Goodman & Gilman's the pharmacological basis of therapeutics (13th ed.). New York: McGraw Hill Education. ISBN   978-1-259-58473-2. OCLC   993810322.
  12. Wormser GP, Chambers HF (2001-02-01). "The Antimicrobial Drugs, Second Edition by Eric Scholar and William Pratt New York: Oxford University Press, 2000. 607 pp., illustrated. $98.50 (cloth); $69.50 (paper)". Clinical Infectious Diseases. 32 (3): 521. doi: 10.1086/318515 . ISSN   1058-4838.
  13. Gelmo P (1908). "Über Sulfamide der p-Amidobenzolsulfonsäure". Journal für Praktische Chemie. 77 (1): 369–382. doi:10.1002/prac.19080770129. ISSN   1521-3897.
  14. "Paul Gelmo". Encyclopedia.com.
  15. Gelmo P (14 May 1908). "Über Sulfamide der p-Amidobenzolsulfonsäure". Journal für Praktische Chemie. 77: 369–382. doi:10.1002/prac.19080770129.
  16. On May 18, 1909, Deutsches Reich Patentschrift number 226,239 for sulfanilamide was awarded to Heinrich Hörlein of the Bayer corporation.
  17. Domagk G (February 15, 1935). "Ein Beitrag zur Chemotherapie der bakteriellen Infektionen". Deutsche Medizinische Wochenschrift. 61 (7): 250. doi:10.1055/s-0028-1129486. S2CID   70515565.
  18. Tréfouël J, Tréfouël T, Nitti F, Bovet D (November 23, 1935). "Activité du p-aminophénylsulfamide sur l'infection streptococcique expérimentale de la souris et du lapin". C. R. Soc. Biol. 120: 756.
  19. Bovet D (1988). "Les étapes de la découverte de la sulfamidochrysoïdine dans les laboratoires de recherche de la firme Bayer à Wuppertal-Elberfeld (1927–1932)". Une chimie qui guérit : Histoire de la découverte des sulfamides. Médecine et Société (in French). Paris: Payot. p. 307.
  20. Ballentine C. "Sulfanilamide Disaster" (PDF). fda.gov. FDA. Retrieved 5 May 2022.